Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification-Reference-Cited by-同舟云学术

Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification

Published:2014-12 Issue:18 Volume:47 Page:272-278
ISSN:0009-9120
Container-title:Clinical Biochemistry
language:en
Short-container-title:Clinical Biochemistry

Author:

Pérez de Ciriza Carmen,Moreno María,Restituto Patricia,Bastarrika Gorka,Simón Isabel,Colina Inmaculada,Varo Nerea

Funder

Sociedad Española de Química Clínica (SEQC)

Publisher

Elsevier BV

Subject

Clinical Biochemistry,General Medicine

Reference34 articles.

1. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity;Venuraju;J Am Coll Cardiol,2010

2. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases;Hofbauer;JAMA,2004

3. Osteoprotegerin: a biomarker with many faces;Caidahl;Arterioscler Thromb Vasc Biol,2010

4. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin;Schoppet;Biochem Biophys Res Commun,2011

5. Osteoprotegerin (OPG) is localized to the Weibel–Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor;Zannettino;J Cell Physiol,2005

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RANKL signaling drives skeletal muscle into the oxidative profile;Journal of Bone and Mineral Research;2024-04-15

2. Value of serum osteoprotegerin in the assessment of endothelial dysfunction in obesity;The Egyptian Journal of Internal Medicine;2024-04-05

3. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease;Current Obesity Reports;2023-05-19

4. RANKL inhibition: a new target of treating diabetes mellitus?;Therapeutic Advances in Endocrinology and Metabolism;2023-01

5. Comparison of novel markers of metabolic complications and cardiovascular risk factors between obese non-diabetic and obese type 1 diabetic children and young adults;Frontiers in Endocrinology;2022-12-12